|
Exhibit 10.1
SCIENTIFIC CONSULTING AGREEMENT
March 21, 2007
TO: Dr. Stephen Stahl
1930 Palomar Point Way, Suite 101
Carlsbad, CA 92008
FROM: Tetragenex Pharmaceuticals, Inc.
We are pleased to engage your services as a consultant to
Tetragenex
Pharmaceuticals, Inc. (the "Company"), and in this letter to
set
forth the terms of your engagement.
1. SERVICES
You agree that you shall serve as lead scientific consultant
and
Chairman of the scientific advisory board to the Company,
specifically by applying your extensive clinical and
research
experience in order to assist the Company on the next phase
of
development for Nemifitide and other development issues with
regard
to other Tetragenex compounds for the terms set forth below.
Duties
as a consultant will include but not be limited to:
o Researching the neurobiological background of nemifitide
and
its related family of compounds, engaging other scientific
consultants to the company, as well as external field
experts
in the process of conducting your research
o Organizing coherent and scientifically accurate
presentation
materials detailing the neurobiology, basic and clinical
pharmacology of nemifitide with regard to its application in
treatment of various central nervous system disorders,
including but not limited to depression
o Presenting neurobiological, pharmacological, and clinical
data
to potential licensing, potential development and potential
investors or investment partners of the company
o Train other scientific consultants to the company in the
aforementioned presentation materials you develop to the
degree they may assist you in presentation, or participate
in
lieu of you should you become unavailable to present on
occasion
o Leveraging your industry expertise and contacts in an
effort
to facilitate obtaining meetings with potential licensing
partners, investors, and clinical investigators
o Serving as the lead scientific expert in the development
of
product key message shaping and marketing plan development
activities for nemifitide and its related family of
compounds
o Assisting as point scientist in the neqotiation proceedings
of
and potential product sale or licensing activities of the
company associated with nemifitide and its related family of
compounds
<PAGE>
o Attending all critical licensing and drug development
meetings
in person with potential pharmaceutical partners
o Working directly or indirectly with other scientific
consultants to the company, as well as external field
experts
as needed
o Working with and coordinating all meetings with Martin
Schacker your point person and other directors at Tetragenex
when Mr. Schacker's not available
o Input into initial protocol design
o Advising with investigator selection
o Reviewing and giving input into collected data
o Participating in "think tank" discussions whether by phone
or
at meetin
| 
